Finian serves as founder and chairman at Vickers Venture Partners and Vickers Financial Group, following investment banking and public sector roles in Singapore.
Jeffrey serves as vice chairman and founding partner at Vickers Venture Partners, alongside holding leadership and board roles across investment and technology firms. He also chairs Vickers Vantage Corp I and acts as an ambassador for the Singapore Venture Capital and Private Equity Association.
Linda brings venture capital experience from Cleveland Clinic Ventures and Vickers Venture Partners, alongside board leadership roles at Steelhead Therapeutics and Mobius Care.
Vickers Venture Partners led the Series A round to support clinical trials for set-point vaccines.
"Attracting such high calibre investors is an endorsement of our development pipeline and validation of the potential our technologies hold in the field of infectious diseases. These new funds will support us to achieve some significant value-enhancing milestones as we progress our lead vaccine candidates into clinical development."
The Series A round was led by Tencent with participation from Graphene Ventures, Bloomberg Beta, Rakuten, Fidelity, and Vickers Venture Partners.
"Today’s announcement amplifies our commitment to global markets, whilst fuelling our industry momentum as we continue to build Everledger. Having this strong investor cohort join us at this stage in our development is both validation of the innovation we’ve displayed to date, and a statement of future intent. They will support us in bringing more visibility to good business practices in industries that impact millions, if not billions of people in developing countries."